Global Minimally Invasive Biopsy Techniques Market stood at USD 4,501.20 million in 2021 and is expected to grow at a CAGR of 12.36% during the forecast period. When compared to open diagnostic surgery, minimally invasive biopsy reduces the number of surgical treatments required. In individuals with suspected or ambiguous breast lesions which can be identified by imaging, minimally invasive biopsy has taken the place of open excisional biopsy. When compared to surgical excision, Minimally Invasive Biopsy (MIB) has a similar or higher level of precision which lessens the psychological toll on the patients and is less economical. Compared to open diagnostic surgery, MIB reduces the number of surgical procedures needed in patients with impalpable cancers like breast cancer. The increased need for biopsy testing to detect cancerous cells, identify autoimmune, inflammatory, and infectious diseases, as well as the wide adoption of less invasive surgical methods has increased in the past few years and has highlighted the need for its further expansion. Early cancer detection and increased precision compared to incisional and excisional biopsies have been the constant drivers of this sector. The biopsy with minimally invasiveness can detect cancer and advance the treatment monitoring and selection. The minimal invasive biopsy can be performed more than one time in comparison to the surgical biopsy for tissue extraction providing more ease in the biopsy process and detection of different type of cancers.

Rise in Cancer Cases Due to Multiple Factors

In many nations with low and medium Human Development Index (HDI), significant lifestyle changes, sociocultural contexts, and environments significantly impact the incidence of risk factors for cancers. The delaying of childbearing and having fewer children, as well as higher levels of excess body weight and physical inactivity, are among the common risk factors which increase the chances of breast cancer. Breast cancer incidence rates are increasing globally. Due to lifestyle variables, including smoking, obesity, and alcohol consumption, cancer tends to be more common in high-income countries. It also predominates in nations with good health care systems, which can identify and cure cancer more effectively than those in low-income countries. Furthermore, cancer survival rates in every nation continue to rise because of developments in medical knowledge and technology. Even while a smaller percentage of cancer patients pass away from the illness, the overall number of cancer-related deaths is rising. This is sometimes ascribed to the fact that the world's population is aging faster than ever before, which increases the risk of developing cancer. The most common ways to express cancer rates are as a crude rate or an age-standardized rate, which accounts for the fact that some nations' populations are often younger than others. Thus, early diagnosis and prevention is the basic step to decreasing the mortality rates, which is now being focused on the implementation of more awareness for the use of minimally invasive techniques for conducting biopsies.

Integration of Artificial Intelligence Will Support the Market Growth

The growing use of robotics in biopsy operations is one of the key trends in the market for minimally invasive biopsy technology. Robotic surgery has increased surgical accuracy and better vision of the operating site. Due to its capacity to offer greater control, and range of motion compared to conventional open operations, these devices are now being used more frequently.

Another development is the use of molecular imaging powered by Artificial Intelligence, which has the potential to significantly improve the diagnosis of colorectal cancer. AI algorithms enable the comparison of a patient's current information with vast databases of patients who have already received treatment, potentially enabling the choice of the best treatment option and the prediction of the outcome of that option. In the case of colorectal cancers, capsule endoscopy (CE), which is a minimally invasive diagnostic method, is a potent alternate strategy. Traditionally, colon CE has been a labor-intensive process that relies on human interpretation and analysis of the photographed pictures to find probable colorectal cancer (CRC) lesions. As the small intestine cannot be reached by traditional upper endoscopy or by colonoscopy, the use of capsule endoscopy provides an accessible way to evaluate the small intestine by the doctor.

Another AI advancement can be seen in liquid biopsies, where due to the size and complexity of the data produced by liquid biopsies, existing approaches are unable to process them efficiently. For automated assessments of these data and future predictions, machine learning is a potential method. Numerous ML techniques, including SVM, random forest (RF), and ANNs, have been successfully applied in the medical industry.

Initiatives at Global Level to Support Market Growth

WHO and IARC have collaborated with other UN organizations to enhance political commitment to cancer prevention and control globally. It aims to carry out research on the causes of human cancer and the mechanisms of carcinogenesis; and interact with other UN entities, including the International Atomic Energy Agency to track the prevalence of cancer (as part of the Global Initiative on Cancer Registries’ activities) to reach out the countries where the availability of data is limited.

It is also focusing to determine the "best buys" and other high-priority, cost-effective cancer preventive and control measures which includes minimally invasive biopsy techniques and is also providing guidelines and standards to direct the development and application of programs for cancer prevention, early detection, screening, treatment, palliative care, and survivorship care in both adults and children.

The initiative also includes creating awareness for the application of minimally invasive biopsy techniques to enhance access to cancer treatments by bolstering local and national health systems.

Increasing Proliferation of the Minimally Invasive Surgical Procedure

Core needle biopsy and fine needle aspiration biopsy are two minimally invasive biopsy methods which are extensively used in breast biopsy and have several advantages over surgical biopsy. The costs are lower, there is less scarring, the diagnostic accuracy is almost the same, and there is no need for general anesthesia or sedation with minimally invasive biopsy. In nations with low resources, where patients frequently arrive with advanced-stage breast cancer, a minimally invasive biopsy can enable accurate diagnosis and quick care in a cost-effective manner. The execution of a successful program in minimally invasive breast biopsy is marked by several events: public awareness of these procedures' for being less invasive in nature, which can encourage women to seek care early; a shift in medical professionals' treatment philosophies that favors patient involvement in decision-making and acceptance of less intrusive but reliable diagnostic techniques.


Download Free Sample Report

Market Segmentation

The Global Minimally Invasive Biopsy Techniques market is segmented based on Product Offered, Technique, Circulating Biomarker, Application, End User, region and company. Based on Product Offered, the market can be split into Tests, Kits & Consumables, Instruments.  Based on Technique, the market is segmented into Liquid Biopsy, Optical Biopsy, Brush Biopsy, Pigmented Lesion Assays, Others. Based on the Circulating Biomarker, the segment is divided into Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs), Cell Free DNA (cfDNA), Extracellular Vesicles, Others. Based on Application, the market is bifurcated into Clinical and Therapeutic application. The Clinical application is sub segmented into Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others. Similarly, the Therapeutic Application is further sub segmented into Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Others. Based on the End User, the market is divided Hospitals & Clinics, Academic & Research Institutions and Ambulatory Care Centers.

Company Profiles

Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche AG, QIAGEN NV, Guardant Health, Inc., Veracyte, Inc., Myriad Genetics, Inc., Biocept, Inc., NeoGenomics Laboratories, Inc., Adaptive Biotechnologies Corporation, DermTech, Inc. are among the major market players operating in the Global Minimally Invasive Biopsy Techniques market.

Attribute

Details

Market size value in 2021

USD 4,501.20 Million

Revenue Forecast in 2027

USD 9,297.72 Million

United States Market Size Value in 2021

USD 1,353.47 Million

Growth Rate

12.36%

Base Year

2021

Historical Years

2017 – 2020

Estimated Year

2022

Forecast Period

2023 – 2027

Quantitative Units

Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027

Report Coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered

·         Product Offered

·         Technique

·         Circulating Biomarker

·         Application

·         End User

Regional Scope

North America; Europe; Asia Pacific; South America; Middle East & Africa

Country Scope

United States; Canada; Mexico; Germany; France; United Kingdom; Italy; Spain; Poland; China; India; Japan; South Korea; Australia; Thailand; Vietnam; Malaysia; Brazil; Argentina; Colombia; Turkey; Egypt; South Africa; Saudi Arabia; UAE

Key Companies Profiled

Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche AG QIAGEN NV, Guardant Health, Inc., Veracyte, Inc., Myriad Genetics, Inc.

Customization Scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/pdf format on special request)

 

Report Scope:

In this report, Global Minimally Invasive Biopsy Techniques market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Minimally Invasive Biopsy Techniques Market, By Product Offered:
    • Tests
    • Kits & Consumables
    • Instruments

·         Minimally Invasive Biopsy Techniques Market, By Technique:

    • Liquid Biopsy
    • Optical Biopsy
    • Brush Biopsy
    • Pigmented Lesion Assays
    • Others (Breath Biopsy etc.)

·         Minimally Invasive Biopsy Techniques Market, By Circulating Biomarker:

o   Circulating Tumor Cells (CTCs)

o   Cell Free DNA (cfDNA)

o   Circulating Tumor DNA (ctDNA)

o   Extracellular Vesicles

o   Others (miRNA, CTECs, circRNA etc.)

·         Minimally Invasive Biopsy Techniques Market, By Application:

o   Clinical

o   Therapeutic

·         Minimally Invasive Biopsy Techniques Market, By Clinical Application

o   Treatment Monitoring

o   Prognosis & Recurrence Monitoring

o   Treatment Selection

o    Others (Diagnosis and Screening etc.)

·         Minimally Invasive Biopsy Techniques Market, By Therapeutic Application

o   Breast Cancer

o   Lung Cancer

o   Prostate Cancer

o   Colorectal Cancer

o   Others (Blood Cancer, Thyroid Cancer etc.)

·         Minimally Invasive Biopsy Techniques Market, By End User:

o   Hospitals & Clinics

o   Ambulatory Care Centers

o   Academic & Research Institutions

  • Minimally Invasive Biopsy Techniques Market, By Region:
    • North America
      • United States
      • Canada
      • Mexico
    •    Europe
      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
      • Poland
    • Asia-Pacific
      • China
      • India
      • Japan
      • South Korea
      • Australia
      • Thailand
      • Vietnam
      • Malaysia 
    • South America
      • Brazil
      • Argentina
      • Colombia
    • Middle East & Africa
      • Turkey
      • Egypt
      • South Africa
      • Saudi Arabia
      • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Minimally Invasive Biopsy Techniques market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com

1.    Service Overview

2.    Research Methodology

3.    Executive Summary

4.    Impact of COVID-19 on Global Minimally Invasive Biopsy Techniques Market

5.    Voice of Customer

6.    Clinical Trial Analysis

7.    Patent Analysis

8.    Global Minimally Invasive Biopsy Techniques Market Outlook

8.1.  Market Size & Forecast

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Product Offered (Tests, Kits & Consumables, Instruments)

8.2.2.     By Technique (Liquid Biopsy, Optical Biopsy, Brush Biopsy, Pigmented Lesion Assays, Others {Breath Biopsy etc.})

8.2.3.     By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free DNA (cfDNA), Circulating Tumor DNA (ctDNA), Extracellular Vesicles, Others {miRNA, CTECs, circRNA etc.})

8.2.4.     By Application (Clinical v/s Therapeutic)

8.2.4.1.         By Clinical Application (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others {Diagnosis and Screening etc.})

8.2.4.2.         By Therapeutic Application (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Others {Blood Cancer, Thyroid Cancer etc.})

8.2.5.     By End User (Hospitals & Clinics, Academic & Research Institutions, Ambulatory Care Centers)

8.2.6.     By Company (2021)

8.2.7.     By Region

8.3.  Market Map

9.    North America Minimally Invasive Biopsy Techniques Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Product Offered (Tests, Kits & Consumables, Instruments)

9.2.2.     By Technique (Liquid Biopsy, Optical Biopsy, Brush Biopsy, Pigmented Lesion Assays, {Breath Biopsy etc.})

9.2.3.     By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free DNA (cfDNA), Circulating Tumor DNA (ctDNA), Extracellular Vesicles, {miRNA, CTECs, circRNA etc.})

9.2.4.     By Application (Clinical v/s Therapeutic)

9.2.4.1.         By Clinical Application (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others {Diagnosis and Screening etc.})

9.2.4.2.         By Therapeutic Application (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Others {Blood Cancer, Thyroid Cancer etc.})

9.2.5.     By End User (Hospitals & Clinics, Academic & Research Institutions, Ambulatory Care Centers)

9.2.6.     By Country

9.3.  North America: Country Analysis

9.3.1.     United States Minimally Invasive Biopsy Techniques Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Product Offered

9.3.1.2.2.             By Technique

9.3.1.2.3.             By Circulating Biomarker

9.3.1.2.4.             By Application

9.3.1.2.5.             By End User

9.3.2.     Canada Minimally Invasive Biopsy Techniques Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Product Offered

9.3.2.2.2.             By Technique

9.3.2.2.3.             By Circulating Biomarker

9.3.2.2.4.             By Application

9.3.2.2.5.             By End User

9.3.3.     Mexico Minimally Invasive Biopsy Techniques Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Product Offered

9.3.3.2.2.             By Technique

9.3.3.2.3.             By Circulating Biomarker

9.3.3.2.4.             By Application

9.3.3.2.5.             By End User

10.  Europe Minimally Invasive Biopsy Techniques Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Product Offered (Tests, Kits & Consumables, Instruments)

10.2.2.  By Technique (Liquid Biopsy, Optical Biopsy, Brush Biopsy, Pigmented Lesion Assays, {Breath Biopsy etc.})

10.2.3.  By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free DNA (cfDNA), Circulating Tumor DNA (ctDNA), Extracellular Vesicles, {miRNA, CTECs, circRNA etc.})

10.2.4.  By Application (Clinical v/s Therapeutic)

10.2.4.1.      By Clinical Application (Treatment Monitoring, Prognosis & Recurrence Monitoring, Treatment Selection, Others {Diagnosis and Screening etc.})

10.2.4.2.      By Therapeutic Application (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Others {Blood Cancer, Thyroid Cancer etc.})

10.2.5.  By End User (Hospitals & Clinics, Academic & Research Institutions, Ambulatory Care Center)

10.2.6.  By Country

10.3.              Europe: Country Analysis

10.3.1.  Germany Minimally Invasive Biopsy Techniques Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Product Offered

10.3.1.2.2.           By Technique

10.3.1.2.3.           By Circulating Biomarker

10.3.1.2.4.           By Application

10.3.1.2.5.           By End User

10.3.2.  France Minimally Invasive Biopsy Techniques Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Product Offered

10.3.2.2.2.           By Technique

10.3.2.2.3.           By Circulating Biomarker

10.3.2.2.4.           By Application

10.3.2.2.5.           By End User

10.3.3.  United Kingdom Minimally Invasive Biopsy Techniques Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Product Offered

10.3.3.2.2.   &n